Fondaparinux Sodium (Page 4 of 13)

Abdominal Surgery

In a randomized study of patients undergoing abdominal surgery, fondaparinux sodium 2.5 mg once daily (n = 1,433) was compared with dalteparin 5,000 IU once daily (n = 1,425). Bleeding rates are shown in Table 3.

Table 3. Bleeding in the Abdominal Surgery Study
*
Major bleeding was defined as bleeding that was (1) fatal, (2) bleeding at the surgical site leading to intervention, (3) non-surgical bleeding at a critical site (e.g. intracranial, retroperitoneal, intraocular, pericardial, spinal, or into adrenal gland), or leading to an intervention, and/or with a bleeding index (BI) ≥2.
†
Minor bleeding was defined as clinically overt bleeding that was not major.

Fondaparinux Sodium

2.5 mg SC once daily

Dalteparin Sodium

5,000 IU SC once daily

N = 1,433

N = 1,425

Major bleeding *

49 (3.4%)

34 (2.4%)

Fatal bleeding

2 (0.1%)

2 (0.1%)

Non-fatal bleeding at critical site

0 (0.0%)

0 (0.0%)

Other non-fatal major bleeding

Surgical site

38 (2.7%)

26 (1.8%)

Non-surgical site

9 (0.6%)

6 (0.4%)

Minor bleeding †

31 (2.2%)

23 (1.6%)

The rates of major bleeding according to the time interval following the first fondaparinux sodium injection were as follows: <6 hours was 3.4% (9/263) and 6 to 8 hours was 2.9% (32/1112).

Treatment of Deep Vein Thrombosis and Pulmonary Embolism

The rates of bleeding events reported during a dose-response trial (n = 111) and an active-controlled trial with enoxaparin sodium in DVT treatment (n = 1,091) and an active-controlled trial with heparin in PE treatment (n = 1,092) with fondaparinux sodium are provided in Table 4.

Table 4. Bleeding * in Deep Vein Thrombosis and Pulmonary Embolism Treatment Studies
*
Bleeding rates are during the study drug treatment period (approximately 7 days). Patients were also treated with vitamin K antagonists initiated within 72 hours after the first study drug administration.
†
Major bleeding was defined as clinically overt: –and/or contributing to death – and/or in a critical organ including intracranial, retroperitoneal, intraocular, spinal, pericardial, or adrenal gland – and/or associated with a fall in hemoglobin level ≥2 g/dL – and/or leading to a transfusion ≥2 units of packed red blood cells or whole blood.
‡
Clinically overt bleeding with a 2 g/dL fall in hemoglobin and/or leading to transfusion of PRBC or whole blood ≥2 units.
§
Minor bleeding was defined as clinically overt bleeding that was not major.

Fondaparinux Sodium

N = 2,294

Enoxaparin Sodium

N = 1,101

Heparin

aPTT adjusted IV

N = 1,092

Major bleeding †

28 (1.2%)

13 (1.2%)

12 (1.1%)

Fatal bleeding

3 (0.1%)

0 (0.0%)

1 (0.1%)

Non-fatal bleeding at a critical site

3 (0.1%)

0 (0.0%)

2 (0.2%)

Intracranial bleeding

3 (0.1%)

0 (0.0%)

1 (0.1%)

Retro-peritoneal bleeding

0 (0.0%)

0 (0.0%)

1 (0.1%)

Other clinically overt bleeding ‡

22 (1.0%)

13 (1.2%)

10 (0.9%)

Minor bleeding §

70 (3.1%)

33 (3.0%)

57 (5.2%)

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

https://medlibrary.org/lib/rx/meds/fondaparinux-sodium-3/page/4/

Clinical Trials

MedLibrary.org

Medication Sections

RSS Feeds

About

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2023. All Rights Reserved.